2021 年第 2 期 第 16 卷

血清微小RNA-623和微小RNA-5703及微小RNA-483-5p与局部晚期食管鳞癌患者新辅助放化疗效果的关系

Relationship between serum microRNA-623, microRNA-5703 and microRNA-483-5p and efficacy of neoadjuvant chemoradioxtherapy in patients with locally advanced esophageal squamous cell carcinoma

作者：陆艳荣巴尔夏古丽·扎比胡拉王海峰

英文作者：Lu Yanrong Baerxiaguli Zhabihula Wang Haifeng 

单位：新疆医科大学附属肿瘤医院胸腹放疗科，乌鲁木齐830011

英文单位：Department of Thoracoabdominal Radiotherapy Cancer Hospital Affiliated to Xinjiang Medical University Urumqi 830011 China

关键词：食管鳞癌；新辅助放化疗；微小RNA-623；微小RNA-5703；微小RNA-483-5p

英文关键词：Esophagealsquamouscellcarcinoma；Neoadjuvantchemoradiotherapy；MicroRNA-623；MicroRNA-5703；MicroRNA-483-5p

• 摘要：

• 目的 探讨血清微小RNA（miR）-623、miR-5703、miR-483-5p表达与局部晚期食管鳞癌患者新辅助放化疗效果的关系。方法 选择2018年6月至2020年6月新疆医科大学附属肿瘤医院收治的86例局部晚期食管鳞癌患者，均给予同步新辅助放化疗，按疗效分为有效组(40例)和无效组(46例)。治疗前后采用实时荧光定量聚合酶链反应检测miR-623、miR-5703、miR-483-5p表达。分析三者表达与局部晚期食管鳞癌患者新辅助放化疗疗效的关系以及三者预测局部晚期食管鳞癌患者新辅助放化疗疗效的价值。结果 治疗后86例患者血清miR-623表达高于治疗前［（5.94±1.43）比（3.15±0.54）］，miR-5703、miR-483-5p表达低于治疗前［（3.37±0.69）比（6.03±1.57）、（2.25±0.35）比（4.35±0.82）］（均P＜0.001）。治疗后有效组血清miR-623表达高于无效组，血清miR-5703、miR-483-5p表达以及低中度分化、深层浸润、TNM分期Ⅲ～Ⅳ期、淋巴结转移者所占比例低于无效组（均P＜0.05）。Logistic回归分析结果显示，淋巴结转移、miR-5703、miR-483-5p高表达，miR-623低表达与局部晚期食管鳞癌新辅助放化疗无效有关（比值比=1.774、1.978、2.032、1.879，95%置信区间：1.653～1.829、1.825～2.135、1.953～2.547、1.720～1.983，P=0.005、＜0.001、＜0.001、0.003）。受试者工作特征曲线分析结果显示，miR-623、miR-5703、miR-483-5p三者联合诊断的曲线下面积高于单独诊断（0.915比0.676、0.755、0.707，均P＜0.05）。结论 局部晚期食管鳞癌新辅助放化疗无效者血清miR-5703、miR-483-5p表达升高，miR-623表达降低，miR-623、miR-5703、miR-483-5p表达与局部晚期食管鳞癌新辅助放化疗效果有关，可以作为疗效评估指标。

• Objective To investigate the relationship between the expressions of serum microRNA(miR)-623, miR-5703, miR-483-5p and the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (LAESCC). Methods A total of 86 patients with LAESCC admitted to Cancer Hospital Affiliated to Xinjiang Medical University from June 2018 to June 2020 were selected and given neoadjuvant chemoradiotherapy. According to curative effect, they were divided into effective group (40 cases) and invalid group (46 cases). The expressions of miR-623, miR-5703 and miR-483-5p were detected by real-time fluorescence quantitative polymerase chain reaction before and after treatment. The relationships between the expressions of miR-623, miR-5703 ，miR-483-5p and the efficacy of neoadjuvant chemoradiotherapy were analyzed, and the value of them in predicting the efficacy of neoadjuvant chemoradiotherapy in patients with LAESCC was analyzed. Results  After treatment, the expression of miR-623 in 86 cases was higher than that before treatment［（5.94±1.43） vs （3.15±0.54）］, and the expressions of serum miR-5703 and miR-483-5p were lower than those before treatment［（3.37±0.69） vs （6.03±1.57）,（2.25±0.35） vs （4.35±0.82）］(all P＜0.001). After treatment, the expression of miR-623 in effective group was higher than that in invalid group, expressions of serum miR-5703, miR-483-5p， rates of low to moderate differentiation, deep invasion, TNM Ⅲ-Ⅳ stage and lymph node metastasis in effective group were lower than those in invalid group(all P＜0.05). Logistic regression analysis showed that lymph node metastasis, high expression of miR-5703 and miR-483-5p, and low expression of miR-623 were associated with ineffective neoadjuvant chemoradiotherapy for LAESCC（odds ratio=1.774, 1.978, 2.032, 1.879， 95% confidence interval： 1.653-1.829, 1.825-2.135, 1.953-2.547, 1.720-1.983, P=0.005, ＜0.001, ＜0.001, 0.003）. Receiver operating characteristic curve analysis showed that the area under curve of combined diagnosis of miR-623, miR-5703, miR-483-5p in predicting the efficacy of neoadjuvant chemoradiotherapy on LAESCC were higher than those of single diagnosis（0.915 vs 0.676, 0.755, 0.707， all P＜0.05）. Conclusions The expressions of serum miR-5703 and miR-483-5p are increased and the expression of miR-623 is decreased in patients with invalid neoadjuvant chemoradiotherapy for LAESCC. The expressions of miR-623, miR-5703 and miR-483-5p are related to the efficacy of neoadjuvant chemoradiotherapy for LAESCC and can be used to efficacy evaluation indexes.